Search

Your search keyword '"Pintado, Vicente"' showing total 268 results
Start Over Author "Pintado, Vicente"
268 results on '"Pintado, Vicente"'

1. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria

Author

Pintado, Vicente, Ruiz-Garbajosa, Patricia, Aguilera-Alonso, David, Baquero-Artigao, Fernando, Bou, Germán, Cantón, Rafael, Grau, Santiago, Gutiérrez-Gutiérrez, Belén, Larrosa, Nieves, Machuca, Isabel, Martínez Martínez, Luis, Montero, María Milagro, Morte-Romea, Elena, Oliver, Antonio, Paño-Pardo, José Ramón, and Sorlí, Luisa

Published
2023
Full Text
View/download PDF

2. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

Author

de la Serna, Almudena, Monteau, Sophie, Palomo, Virginia, Soriano, Elena, Gutierrez, David, Moreno, Elisa, Palacios, Zaira, Morales, Isabel, Maldonado, Natalia, Ciezar, Antonio Plata, Ruiz Mesa, Juan Diego, Diaz, Beatriz Sobrino, Gomez, Ignacio Marquez, Camacho, Ines Perez, Frutos-Adame, Azahara, Guzman-Puche, Julia, Gracia-Ahufinger, Irene, Perez-Nadales, Elena, Torre-Gimenez, Julian, Pyrpasopoulou, Athina, Iosifidis, Elias, Chorafa, Elsa, Radovanovic, Ivana, Petrovic, Sladjana, Cvetkovi, Slavica, Melentijevic, Srdjan-Sanja, Bicmen, Can, Senol, Gunes, Tubau, Fe, Camara, Jordi, Gumucio, Victor Daniel, Bassoulis, Dimitris, Deliolanis, John, Pitiriga, Vassiliki Ch., Triarides, Nikolaos, Argiti, Efstathia, Legakis, Nikolaos J., Margarita, Kyriakidou, Gijón-Cordero, Desirée, Ruiz-Garbajosa, Patricia, Bartoloni, Alessandro, Rossolini, Gian Maria, Florescu, Simin-Aysel, Nica, Maria, Benea, Serban, Talapan, Daniela, Medić, Deana, Prijić, Sanja Maričić, Caballero, Mireia Cantero, Parra Ramírez, Lina M., Korten, Volkan, Bilgin, Hüseyin, Dalekos, George N., Stefos, Aggelos, Spyridis, Nikolaos, Michos, Athanasios, De Rosa, Francesco Giuseppe, Cavallo, Rossana, Petrosillo, Nicola, Dicaro, Antonio, Landini, Maria Paola, Ciofi degli Atti, Marta Luisa, Masanovic, Mileva, Matkovic, Dusan, Tsiodras, Sotirios, Blasi, Francesco, Di pasquale, Marta, Viscoli, Claudio, Vata, Andrei, Dorneanu, Olivia, Kapisyzi, Perlat, Vince, Adriana, Tsigou, Evdoxia, Maltezos, Efstratios, Komnos, Apostolos, Gogos, Charalampos, Franzetti, Fabio, Antonelli, Massimo, Lupse, Mihaela, Corneci, Dan, Tomescu, Dana, Georgescu, Anca, Bukarica, Ljiljana, Mitrović, Goran, Krstić, Nataša Lukić, Kurti, Arsim, Díaz-Pollán, Beatriz, Sabater, Julia Origüen, Muñoz, Patricia, Azap, Alpay, Sancak, Banu, Sahin, Arife, Akalin, Halis, Pérez-Galera, Salvador, Bravo-Ferrer, Jose M., Paniagua, María, Kostyanev, Tomislav, de Kraker, Marlieke E.A., Feifel, Jan, Sojo-Dorado, Jesús, Schotsman, Joost, Cantón, Rafael, Daikos, George L., Carevic, Biljana, Dragovac, Gorana, Tan, Lionel K., Raka, Lul, Hristea, Adriana, Viale, Pierluigi, Akova, Murat, Reguera, Jose María, Valiente de Santis, Lucía, Torre-Cisneros, Julián, Cano, Ángela, Roilides, Emmanuel, Radulovic, Lili, Kirakli, Cenk, Shaw, Evelyn, Falagas, Matthew E., Pintado, Vicente, Goossens, Herman, Bonten, Marc J., Gutiérrez-Gutiérrez, Belén, and Rodriguez-Baño, Jesús

Published
2023
Full Text
View/download PDF

4. Risk factors for bloodstream infections due to carbapenem-resistant Enterobacterales: a nested case-control-control study.

Author

Zhou, Hongyu, Buetti, Niccolò, Pérez-Galera, Salvador, Bravo-Ferrer, Jose, Gutiérrez-Gutiérrez, Belén, Paniagua-García, María, Feifel, Jan, Sauser, Julien, Kostyanev, Tomi, Canton, Rafael, Tan, Lionel K, Basoulis, Dimitris, Pintado, Vicente, Roilides, Emmanuel, Dragovac, Gorana, Torre-Cisneros, Julian, Mediç, Deana, Akova, Murat, Goossens, Herman, and Bonten, Marc

Subjects
INFECTION prevention, COLONIZATION (Ecology), MEDICAL referrals, ANTIMICROBIAL stewardship, LONG-term health care, LONG-term care facilities
Abstract

Background Carbapenem-resistant Enterobacterales (CRE) bloodstream infections (BSIs) are a major threat to patients. To date, data on risk factors have been limited, with low internal and external validity. In this multicentre study, risk factors for CRE BSI were determined by comparison with two control groups: patients with carbapenem-susceptible Enterobacterales (CSE) BSI, and patients without Enterobacterales infection (uninfected patients). Methods A multicentre, case-control-control study was nested in a European prospective cohort study on CRE (EURECA). CRE BSI:CSE BSI matching was 1:1, CRE BSI:Uninfected patients matching was 1:3, based on hospital, ward and length of stay. Conditional logistic regression was applied. Results From March 2016 to November 2018, 73 CRE BSIs, 73 CSE BSIs and 219 uninfected patients were included from 18 European hospitals. For CRE versus CSE BSI, previous CRE colonization/infection [incidence rate ratio (IRR) 7.32; 95% CI 1.65–32.38) increased the risk. For CRE versus uninfected controls, independent risk factors included: older age (IRR 1.03; 95% CI 1.01–1.06), patient referral (long-term care facility: IRR 7.19; 95% CI 1.51–34.24; acute care hospital: IRR 5.26; 95% CI 1.61–17.11), previous colonization/infection with other MDR organisms (MDROs) (IRR 9.71; 95% CI 2.33–40.56), haemodialysis (IRR 8.59; 95% CI 1.82–40.53), invasive procedures (IRR 5.66; 95% CI 2.11–15.16), and β-lactam/β-lactamase inhibitor combinations (IRR 3.92; 95% CI 1.68–9.13) or third/fourth generation cephalosporin (IRR 2.75; 95% CI 1.06–7.11) exposure within 3 months before enrolment. Conclusions Evidence of previous CRE colonization/infection was a major risk factor for carbapenem resistance among Enterobacterales BSI. Compared with uninfected patients, evidence of previous MDRO colonization/infection and healthcare exposure were important risk factors for CRE BSI. Targeted screening, infection prevention and antimicrobial stewardship should focus on these high-risk patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Risk factors for bloodstream infections due to carbapenem-resistant Enterobacterales: a nested case-control-control study

Author

Epi Infectieziekten, Infection & Immunity, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectious Diseases, Zhou, Hongyu, Buetti, Niccolò, Pérez-Galera, Salvador, Bravo-Ferrer, Jose, Gutiérrez-Gutiérrez, Belén, Paniagua-García, María, Feifel, Jan, Sauser, Julien, Kostyanev, Tomi, Canton, Rafael, Tan, Lionel K, Basoulis, Dimitris, Pintado, Vicente, Roilides, Emmanuel, Dragovac, Gorana, Torre-Cisneros, Julian, Mediç, Deana, Akova, Murat, Goossens, Herman, Bonten, Marc, Harbarth, Stephan, Rodriguez-Baño, Jesus, De Kraker, Marlieke E A, COMBACTE- EURECA project team, Epi Infectieziekten, Infection & Immunity, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectious Diseases, Zhou, Hongyu, Buetti, Niccolò, Pérez-Galera, Salvador, Bravo-Ferrer, Jose, Gutiérrez-Gutiérrez, Belén, Paniagua-García, María, Feifel, Jan, Sauser, Julien, Kostyanev, Tomi, Canton, Rafael, Tan, Lionel K, Basoulis, Dimitris, Pintado, Vicente, Roilides, Emmanuel, Dragovac, Gorana, Torre-Cisneros, Julian, Mediç, Deana, Akova, Murat, Goossens, Herman, Bonten, Marc, Harbarth, Stephan, Rodriguez-Baño, Jesus, De Kraker, Marlieke E A, and COMBACTE- EURECA project team

Published
2024

8. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort

Author

Moreno, Santiago, Pérez-Elías, Maria Jesús, Fortún, Jesús, Navas, Enrique, Quereda, Carmen, Dronda, Fernando, Del Campo, Santos, López-Vélez, Rogelio, Cobo Reinoso, Javier, Casado, José Luis, Moreno, Ana, Norman, Franceca, Martín-Dávila, Pilar, Hermida, José Manuel, Pérez Molina, José Antonio, Monge, Begoña, Pintado, Vicente, Serrano-Villar, Sergio, Sánchez-Conde, Matilde, Chamorro, Sandra, Escudero, Rosa, Gioia, Francesca, Comeche, Belén, Crespillo, Clara, Herrera, Sabina, Ron, Raquel, Martínez-Sanz, Javier, Pons-Guillén, Mario, Vivancos, María Jesús, Vizcarra, Pilar, Pérez-Elías, María J, Vivancos, María J, and Casado, José L

Published
2020
Full Text
View/download PDF

9. Multicentre study of cefiderocol for treatment of Gram-negative bacteria infections in critically ill patients

Author

Balandín, Bárbara, Pintado, Vicente, Pérez-Pedrero, María José, Martínez-Sagasti, Fernando, Sancho-González, Milagros, Soriano-Cuesta, Cruz, Gesso, Cristina Martín-Dal, Chicot, Marta, de Luna, Rafael Ruiz, Asensio-Martín, María José, Catalan, Mercedes, Díaz-Díaz, Juan José, Carbonell, Nieves, Iranzo, Reyes, Royuela, Ana, and Ballesteros, Daniel

Published
2024
Full Text
View/download PDF

10. Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae : Results From the INCREMENT Cohort

Author

Spanish Network for Research in Infectious Diseases (REIPI)/European Study Group of Bloodstream Infections and Sepsis (ESGBIS)/INCREMENT Group, Palacios-Baena, Zaira Raquel, Gutiérrez-Gutiérrez, Belén, Calbo, Esther, Almirante, Benito, Viale, Pierluigi, Oliver, Antonio, Pintado, Vicente, Gasch, Oriol, Martínez-Martínez, Luis, Pitout, Johann, Akova, Murat, Peña, Carmen, Gil-Bermejo, José Molina, Hernández, Alicia, Venditti, Mario, Prim, Nuria, Bou, German, Tacconelli, Evelina, Tumbarello, Mario, Hamprecht, Axel, Giamarellou, Helen, Almela, Manel, Pérez, Federico, Schwaber, Mitchell J., Bermejo, Joaquín, Lowman, Warren, Hsueh, Po-Ren, Paño-Pardo, José Ramón, Torre-Cisneros, Julián, Souli, Maria, Bonomo, Robert A., Carmeli, Yehuda, Paterson, David L., Pascual, Álvaro, and Rodríguez-Baño, Jesús

Published
2017

11. Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial

Author

Sojo-Dorado, Jesús, primary, López-Hernández, Inmaculada, additional, Hernández-Torres, Alicia, additional, Retamar-Gentil, Pilar, additional, Merino de Lucas, Esperanza, additional, Escolà-Vergé, Laura, additional, Bereciartua, Elena, additional, García-Vázquez, Elisa, additional, Pintado, Vicente, additional, Boix-Palop, Lucía, additional, Natera-Kindelán, Clara, additional, Sorlí, Luisa, additional, Borrell, Nuria, additional, Amador-Prous, Concha, additional, Shaw, Evelyn, additional, Jover-Saenz, Alfredo, additional, Molina, Jose, additional, Martínez-Álvarez, Rosa M, additional, Dueñas, Carlos J, additional, Calvo-Montes, Jorge, additional, Lecuona, María, additional, Pomar, Virginia, additional, Borreguero, Irene, additional, Palomo-Jiménez, Virginia, additional, Docobo-Pérez, Fernando, additional, Pascual, Álvaro, additional, and Rodríguez-Baño, Jesús, additional

Published
2023
Full Text
View/download PDF

13. COVID-19 and geographical area of origin

Author

Vizcarra, Pilar, Norman, Francesca, Crespillo, Clara, Pérez-Molina, José, Comeche, Belén, Chamorro, Sandra, Monge, Begoña, Moreno, Santiago, López-Vélez, Rogelio, Pérez-Elías, Maria Jesús, Fortún, Jesús, Navas, Enrique, Quereda, Carmen, Dronda, Fernando, Del Campo, Santos, Reinoso, Javier Cobo, Casado, José Luis, Moreno, Ana, Martín-Dávila, Pilar, Hermida, José Manuel, Pintado, Vicente, Serrano-Villar, Sergio, Sánchez-Conde, Matilde, Escudero, Rosa, Gioia, Francesca, Herrera, Sabina, Ron, Raquel, Martínez-Sanz, Javier, Pons-Guillén, Mario, Vivancos, María Jesús, Norman, Francesca F., Crespillo-Andújar, Clara, Pérez-Molina, José Antonio, Monge-Maillo, Begoña, and Moreno-Guillén, Santiago

Published
2021
Full Text
View/download PDF

14. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

Author

Pérez-Galera, Salvador, primary, Bravo-Ferrer, Jose M., additional, Paniagua, María, additional, Kostyanev, Tomislav, additional, de Kraker, Marlieke E.A., additional, Feifel, Jan, additional, Sojo-Dorado, Jesús, additional, Schotsman, Joost, additional, Cantón, Rafael, additional, Daikos, George L., additional, Carevic, Biljana, additional, Dragovac, Gorana, additional, Tan, Lionel K., additional, Raka, Lul, additional, Hristea, Adriana, additional, Viale, Pierluigi, additional, Akova, Murat, additional, Reguera, Jose María, additional, Valiente de Santis, Lucía, additional, Torre-Cisneros, Julián, additional, Cano, Ángela, additional, Roilides, Emmanuel, additional, Radulovic, Lili, additional, Kirakli, Cenk, additional, Shaw, Evelyn, additional, Falagas, Matthew E., additional, Pintado, Vicente, additional, Goossens, Herman, additional, Bonten, Marc J., additional, Gutiérrez-Gutiérrez, Belén, additional, Rodriguez-Baño, Jesús, additional, de la Serna, Almudena, additional, Monteau, Sophie, additional, Palomo, Virginia, additional, Soriano, Elena, additional, Gutierrez, David, additional, Moreno, Elisa, additional, Palacios, Zaira, additional, Morales, Isabel, additional, Maldonado, Natalia, additional, Ciezar, Antonio Plata, additional, Ruiz Mesa, Juan Diego, additional, Diaz, Beatriz Sobrino, additional, Gomez, Ignacio Marquez, additional, Camacho, Ines Perez, additional, Frutos-Adame, Azahara, additional, Guzman-Puche, Julia, additional, Gracia-Ahufinger, Irene, additional, Perez-Nadales, Elena, additional, Torre-Gimenez, Julian, additional, Pyrpasopoulou, Athina, additional, Iosifidis, Elias, additional, Chorafa, Elsa, additional, Radovanovic, Ivana, additional, Petrovic, Sladjana, additional, Cvetkovi, Slavica, additional, Melentijevic, Srdjan-Sanja, additional, Bicmen, Can, additional, Senol, Gunes, additional, Tubau, Fe, additional, Camara, Jordi, additional, Gumucio, Victor Daniel, additional, Bassoulis, Dimitris, additional, Deliolanis, John, additional, Pitiriga, Vassiliki Ch., additional, Triarides, Nikolaos, additional, Argiti, Efstathia, additional, Legakis, Nikolaos J., additional, Margarita, Kyriakidou, additional, Gijón-Cordero, Desirée, additional, Ruiz-Garbajosa, Patricia, additional, Bartoloni, Alessandro, additional, Rossolini, Gian Maria, additional, Florescu, Simin-Aysel, additional, Nica, Maria, additional, Benea, Serban, additional, Talapan, Daniela, additional, Medić, Deana, additional, Prijić, Sanja Maričić, additional, Caballero, Mireia Cantero, additional, Parra Ramírez, Lina M., additional, Korten, Volkan, additional, Bilgin, Hüseyin, additional, Dalekos, George N., additional, Stefos, Aggelos, additional, Spyridis, Nikolaos, additional, Michos, Athanasios, additional, De Rosa, Francesco Giuseppe, additional, Cavallo, Rossana, additional, Petrosillo, Nicola, additional, Dicaro, Antonio, additional, Landini, Maria Paola, additional, Ciofi degli Atti, Marta Luisa, additional, Masanovic, Mileva, additional, Matkovic, Dusan, additional, Tsiodras, Sotirios, additional, Blasi, Francesco, additional, Di pasquale, Marta, additional, Viscoli, Claudio, additional, Vata, Andrei, additional, Dorneanu, Olivia, additional, Kapisyzi, Perlat, additional, Vince, Adriana, additional, Tsigou, Evdoxia, additional, Maltezos, Efstratios, additional, Komnos, Apostolos, additional, Gogos, Charalampos, additional, Franzetti, Fabio, additional, Antonelli, Massimo, additional, Lupse, Mihaela, additional, Corneci, Dan, additional, Tomescu, Dana, additional, Georgescu, Anca, additional, Bukarica, Ljiljana, additional, Mitrović, Goran, additional, Krstić, Nataša Lukić, additional, Kurti, Arsim, additional, Díaz-Pollán, Beatriz, additional, Sabater, Julia Origüen, additional, Muñoz, Patricia, additional, Azap, Alpay, additional, Sancak, Banu, additional, Sahin, Arife, additional, and Akalin, Halis, additional

Published
2023
Full Text
View/download PDF

15. Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial

Author

Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Spanish Clinical Research Network, Sojo-Dorado, Jesús, López-Hernández, Inmaculada, Hernández Torres, Alicia, Retamar Gentil, Pilar, Merino de Lucas, Esperanza, Escolà‐Vergé, Laura, Bereciartúa, Elena, García-Vázquez, Elisa, Pintado, Vicente, Boix-Palop, Lucía, Natera Kindelán, Clara, Sorlí, Luisa, Borrell, Nuria, Amador, Concha, Shaw, Evelyn, Jover-Sáenz, Alfredo, Molina, José, Martínez-Álvarez, Rosa M., Dueñas, Carlos, Calvo-Montes, Jorge, Lecuona, María, Pomar, Virginia, Borreguero, Irene, Palomo, Virginia, Docobo-Pérez, Fernando, Pascual, Álvaro, Rodríguez-Baño, Jesús, on behalf of CIBERINFEC-GEIRAS-FOREST group, Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), European Commission, Spanish Clinical Research Network, Sojo-Dorado, Jesús, López-Hernández, Inmaculada, Hernández Torres, Alicia, Retamar Gentil, Pilar, Merino de Lucas, Esperanza, Escolà‐Vergé, Laura, Bereciartúa, Elena, García-Vázquez, Elisa, Pintado, Vicente, Boix-Palop, Lucía, Natera Kindelán, Clara, Sorlí, Luisa, Borrell, Nuria, Amador, Concha, Shaw, Evelyn, Jover-Sáenz, Alfredo, Molina, José, Martínez-Álvarez, Rosa M., Dueñas, Carlos, Calvo-Montes, Jorge, Lecuona, María, Pomar, Virginia, Borreguero, Irene, Palomo, Virginia, Docobo-Pérez, Fernando, Pascual, Álvaro, Rodríguez-Baño, Jesús, and on behalf of CIBERINFEC-GEIRAS-FOREST group

Abstract

[Background] Fosfomycin is a potentially attractive option as step-down therapy for bacteraemic urinary tract infections (BUTI), but available data are scarce. Our objective was to compare the effectiveness and safety of fosfomycin trometamol and other oral drugs as step-down therapy in patients with BUTI due to MDR Escherichia coli (MDR-Ec)., [Methods] Participants in the FOREST trial (comparing IV fosfomycin with ceftriaxone or meropenem for BUTI caused by MDR-Ec in 22 Spanish hospitals from June 2014 to December 2018) who were stepped-down to oral fosfomycin (3 g q48h) or other drugs were included. The primary endpoint was clinical and microbiological cure (CMC) 5–7 days after finalization of treatment. A multivariate analysis was performed using logistic regression to estimate the association of oral step-down with fosfomycin with CMC adjusted for confounders., [Results] Overall, 61 patients switched to oral fosfomycin trometamol and 47 to other drugs (cefuroxime axetil, 28; amoxicillin/clavulanic acid and trimethoprim/sulfamethoxazole, 7 each; ciprofloxacin, 5) were included. CMC was reached by 48/61 patients (78.7%) treated with fosfomycin trometamol and 38/47 (80.9%) with other drugs (difference, −2.2; 95% CI: −17.5 to 13.1; P = 0.38). Subgroup analyses provided similar results. Relapses occurred in 9/61 (15.0%) and 2/47 (4.3%) of patients, respectively (P = 0.03). The adjusted OR for CMC was 1.11 (95% CI: 0.42–3.29, P = 0.75). No relevant differences in adverse events were seen., [Conclusions] Fosfomycin trometamol might be a reasonable option as step-down therapy in patients with BUTI due to MDR-Ec but the higher rate of relapses would need further assessment.

Published
2023

17. Executive summary of the diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)

Author

Rodríguez-Baño, Jesús, Cisneros, José Miguel, Cobos-Trigueros, Nazaret, Fresco, Gema, Navarro-San Francisco, Carolina, Gudiol, Carlota, Horcajada, Juan Pablo, López-Cerero, Lorena, Martínez, José Antonio, Molina, José, Montero, Milagro, Paño-Pardo, José R., Pascual, Alvaro, Peña, Carmen, Pintado, Vicente, Retamar, Pilar, Tomás, María, Borges-Sa, Marcio, Garnacho-Montero, José, and Bou, Germán

Published
2015
Full Text
View/download PDF

20. Revisión sistemática de la literatura y análisis de expertos sobre los factores de riesgo asociados a infecciones causadas por Pseudomonas aeruginosa o Acinetobacter baumannii resistentes a carbapenémicos en pacientes adultos en España

Author

Ferrer, Ricard, Soriano, Alex, Cantón, Rafael, Del Pozo, José Luis, García-Vidal, Carol, Garnacho-Montero, José, Larrosa, Nieves, Rascado, Pedro, Salavert, Miguel, Pintado, Vicente, Pellicer, Beatriz, and Badía, Xavier

Subjects
Acinetobacter baumannii, resistencia a carbapenémicos, risk factor, factor de riesgo, Pseudomonas aeruginosa, carbapenem resistance, Revisión Sistemática
Abstract

RESUMEN Objetivo El objetivo del estudio es identificar los factores de riesgo asociados a infecciones por Pseudomonas aeruginosa resistente a antibióticos carbapenémicos (PARC) y Acinetobacter baumannii resistente a antibióticos carbapenémicos (ABRC) en pacientes adultos a través de una revisión sistemática de la literatura, clasificarlos según su nivel de importancia y exponer las recomendaciones en el entorno español de un panel de expertos. Material y métodos Se llevó a cabo una revisión sistemática de la literatura para identificar los factores de riesgo asociados a PARC o ABRC y posteriormente evaluar cada factor de riesgo por un panel de expertos basándose en la evidencia disponible y su experiencia en la práctica clínica. Resultados Se identificaron 593 artículos incluyéndose 29 para PARC y 23 para ABRC. Se identificaron 38 factores de riesgo asociados a PARC y 36 factores de riesgo asociados a ABRC. Tras su evaluación, para PARC, se clasificaron en: 11 importantes, 10 moderadamente importantes y 15 poco importantes; y para ABRC, 9 importantes, 5 moderadamente importantes y 19 poco importantes. Para ambos patógenos, los factores de riesgo importantes estuvieron relacionados con el uso previo de antibióticos y la hospitalización. Conclusión Se han identificado los principales factores de riesgo asociados a PARC y ABRC mediante una revisión de la evidencia disponible. Sin embargo, son necesarios estudios adicionales prospectivos que permitan identificar los pacientes con infecciones por dichos patógenos.

Published
2021

21. A systematic literature review and expert consensus on risk factors associated to infection progression in adult patients with respiratory tract or rectal colonisation by carbapenem-resistant Gram-negative bacteria

Author

Ferrer, Ricard, primary, Soriano, Alex, additional, Cantón, Rafael, additional, Del Pozo, José Luis, additional, García-Vidal, Carolina, additional, Garnacho-Montero, José, additional, Larrosa, Nieves, additional, Rascado, Pedro, additional, Salavert, Miguel, additional, Pintado, Vicente, additional, Giró-Perafita, Ariadna, additional, and Badia, Xavier, additional

Published
2022
Full Text
View/download PDF

22. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria

Author

Pintado, Vicente, primary, Ruiz-Garbajosa, Patricia, additional, Aguilera-Alonso, David, additional, Baquero-Artigao, Fernando, additional, Bou, Germán, additional, Cantón, Rafael, additional, Grau, Santiago, additional, Gutiérrez-Gutiérrez, Belén, additional, Larrosa, Nieves, additional, Machuca, Isabel, additional, Martínez Martínez, Luis, additional, Montero, María Milagro, additional, Morte-Romea, Elena, additional, Oliver, Antonio, additional, Paño-Pardo, José Ramón, additional, and Sorlí, Luisa, additional

Published
2022
Full Text
View/download PDF

23. Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial

Author

Comisión Asesora de Investigación Científica y Técnica, CAICYT (España), Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Red Española de Investigación en Patología Infecciosa, European Commission, Sojo-Dorado, Jesús, López-Hernández, Inmaculada, Rosso-Fernández, Clara, Morales, Isabel, Palacios-Baena, Zaira Raquel, Hernández Torres, Alicia, Merino de Lucas, Esperanza, Escolà‐Vergé, Laura, Bereciartúa, Elena, García Vázquez, Elisa, Pintado, Vicente, Boix-Palop, Lucía, Natera Kindelán, Clara, Sorlí, Luisa, Borrell, Núria, Giner Oncina, Livia, Amador, Concha, Shaw, Evelyn, Jover-Sáenz, Alfredo, Molina Gil-Bermejo, José, Martínez Alvarez, R. M., Dueñas, Carlos, Calvo-Montes, Jorge, Silva, José Tiago, Cárdenes, Miguel A., Lecuona, María, Pomar, Virginia, Valiente de Santis, Lucía, Yagüe-Guirao, Genoveva, Lobo Acosta, María Ángeles, Merino-Bohórquez, V., Pascual, Álvaro, Rodríguez-Baño, Jesús, Comisión Asesora de Investigación Científica y Técnica, CAICYT (España), Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades (España), Agencia Estatal de Investigación (España), Red Española de Investigación en Patología Infecciosa, European Commission, Sojo-Dorado, Jesús, López-Hernández, Inmaculada, Rosso-Fernández, Clara, Morales, Isabel, Palacios-Baena, Zaira Raquel, Hernández Torres, Alicia, Merino de Lucas, Esperanza, Escolà‐Vergé, Laura, Bereciartúa, Elena, García Vázquez, Elisa, Pintado, Vicente, Boix-Palop, Lucía, Natera Kindelán, Clara, Sorlí, Luisa, Borrell, Núria, Giner Oncina, Livia, Amador, Concha, Shaw, Evelyn, Jover-Sáenz, Alfredo, Molina Gil-Bermejo, José, Martínez Alvarez, R. M., Dueñas, Carlos, Calvo-Montes, Jorge, Silva, José Tiago, Cárdenes, Miguel A., Lecuona, María, Pomar, Virginia, Valiente de Santis, Lucía, Yagüe-Guirao, Genoveva, Lobo Acosta, María Ángeles, Merino-Bohórquez, V., Pascual, Álvaro, and Rodríguez-Baño, Jesús

Abstract

[Importance] The consumption of broad-spectrum drugs has increased as a consequence of the spread of multidrug-resistant (MDR) Escherichia coli. Finding alternatives for these infections is critical, for which some neglected drugs may be an option., [Objective] To determine whether fosfomycin is noninferior to ceftriaxone or meropenem in the targeted treatment of bacteremic urinary tract infections (bUTIs) due to MDR E coli., [Design, Setting, and Participants] This multicenter, randomized, pragmatic, open clinical trial was conducted at 22 Spanish hospitals from June 2014 to December 2018. Eligible participants were adult patients with bacteremic urinary tract infections due to MDR E coli; 161 of 1578 screened patients were randomized and followed up for 60 days. Data were analyzed in May 2021., [Interventions] Patients were randomized 1 to 1 to receive intravenous fosfomycin disodium at 4 g every 6 hours (70 participants) or a comparator (ceftriaxone or meropenem if resistant; 73 participants) with the option to switch to oral fosfomycin trometamol for the fosfomycin group or an active oral drug or parenteral ertapenem for the comparator group after 4 days., [Main Outcomes and Measures] The primary outcome was clinical and microbiological cure (CMC) 5 to 7 days after finalization of treatment; a noninferiority margin of 7% was considered., [Results] Among 143 patients in the modified intention-to-treat population (median [IQR] age, 72 [62-81] years; 73 [51.0%] women), 48 of 70 patients (68.6%) treated with fosfomycin and 57 of 73 patients (78.1%) treated with comparators reached CMC (risk difference, −9.4 percentage points; 1-sided 95% CI, −21.5 to ∞ percentage points; P = .10). While clinical or microbiological failure occurred among 10 patients (14.3%) treated with fosfomycin and 14 patients (19.7%) treated with comparators (risk difference, −5.4 percentage points; 1-sided 95% CI, −∞ to 4.9; percentage points; P = .19), an increased rate of adverse event–related discontinuations occurred with fosfomycin vs comparators (6 discontinuations [8.5%] vs 0 discontinuations; P = .006). In an exploratory analysis among a subset of 38 patients who underwent rectal colonization studies, patients treated with fosfomycin acquired a new ceftriaxone-resistant or meropenem-resistant gram-negative bacteria at a decreased rate compared with patients treated with comparators (0 of 21 patients vs 4 of 17 patients [23.5%]; 1-sided P = .01)., [Conclusions and Relevance] This study found that fosfomycin did not demonstrate noninferiority to comparators as targeted treatment of bUTI from MDR E coli; this was due to an increased rate of adverse event–related discontinuations. This finding suggests that fosfomycin may be considered for selected patients with these infections.

Published
2022

24. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-β-lactamase-producing Enterobacteriaceae

Author

Palacios-Baena, Zaira Raquel, Gutiérrez-Gutiérrez, Belén, De Cueto, Marina, Viale, Pierluigi, Venditti, Mario, Hernández-Torres, Alicia, Oliver, Antonio, Martínez-Martínez, Luis, Calbo, Esther, Pintado, Vicente, Gasch, Oriol, Almirante, Benito, Antonio Lepe, José, Pitout, Johann, Akova, Murat, Peña-Miralles, Carmen, Schwaber, Mitchell J., Tumbarello, Mario, Tacconelli, Evelina, Origüen, Julia, Prim, Nuria, Bou, German, Giamarellou, Helen, Bermejo, Joaquín, Hamprecht, Axel, Pérez, Federico, Almela, Manuel, Lowman, Warren, Hsueh, Po-Ren, Navarro-San Francisco, Carolina, Torre-Cisneros, Julián, Carmeli, Yehuda, Bonomo, Robert A., Paterson, David L., Pascual, Álvaro, and Rodríguez-Baño, Jesús

Published
2017
Full Text
View/download PDF

25. Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients

Author

Balandín, Bárbara, primary, Ballesteros, Daniel, additional, Pintado, Vicente, additional, Soriano-Cuesta, Cruz, additional, Cid-Tovar, Irene, additional, Sancho-González, Milagros, additional, Pérez-Pedrero, María José, additional, Chicot, Marta, additional, Asensio-Martín, María José, additional, Silva, José Alberto, additional, de Luna, Rafael Ruiz, additional, Gesso, Cristina Martín-Dal, additional, Rodríguez-Serrano, Diego Aníbal, additional, Martínez-Sagasti, Fernando, additional, and Royuela, Ana, additional

Published
2022
Full Text
View/download PDF

26. Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections

Author

Sojo Dorado, Jesús, López Hernández, Inmaculada, Rosso Fernández, Clara, Morales, Isabel M., Palacios Baena, Zaira R., Hernández Torres, Alicia, Merino de Lucas, Esperanza, Escolà Vergé, Laura, Bereciartua, Elena, García Vázquez, Elisa, Pintado, Vicente, Boix Palop, Lucía, Natera Kindelán, Clara, Sorlí, Luisa, Borrell, Nuria, Giner Oncina, Livia, Amador Prous, Concha, Shaw, Evelyn, Jover Saenz, Alfredo, Molina, Jose, Martínez Álvarez, Rosa M., Dueñas, Carlos J., Calvo Montes, Jorge, Silva, Jose T., Cárdenes, Miguel A., Lecuona, María, Pomar, Virginia, Valiente de Santis, Lucía, Yagüe Guirao, Genoveva, Lobo Acosta, María Angeles, Merino Bohórquez, Vicente, Pascual, Alvaro, Rodríguez Baño, Jesús, Almirante, Benito, Fernández, Mario, Paño Pardo, José Ramón, Cueto, Marina de, Retamar Gentil, Pilar, López Cortés, Luis Eduardo, Gutiérrez Gutiérrez, Belén, Docobo, Fernando, Borreguero, Irene, Camean, Manuel, Moral Escudero, Encarnación, Pareja Rodríguez de Vera, Ana, Martínez Toldos, María del Carmen, Blázquez Abellán, Ana, Belles Belles, Alba, Ramírez Hidalgo, María Fernanda, Mirelis, Beatriz, Calbo, Esther, Xercavins, Mariona, Gracia Ahufinger, Irene, Cano Yuste, Angela M., Guío, Laura, Hernandez, Jose Luis, Pigrau Serrallach, Carlos, Viñado Pérez, Belen, Puig Asensio, Mireia, Ardanuy, Carmen, Pujol, Miquel, García Rosado, Dácil, Gil Anguita, Concepción, Siverio, Ana, Gimeno Gascón, Adelina, Boix Martínez, Vicente, Reus Bañuls, Sergio, Agea Durán, Iván, Fariñas, Carmen, Palop, Begoña, Vilchez, Helem, Lepe, José Antonio, Gil Navarro, María Victoria, San Juan, Rafael, Chaves, Fernando, Escudero, Rosa, Gioia, Francesca, Sánchez Díaz, Ana María, Cañas Pedrosa, Ana, Sangil Monroy, Nayra, Toyas Miazza, Carla, and Reipi Geiras Forest Group

Subjects
Escheríchia coli, Infeccions del tracte urinari, Escherichia coli, Urinary tract infections
Abstract

IMPORTANCE The consumption of broad-spectrum drugs has increased as a consequence of the spread of multidrug-resistant (MDR) Escherichia coli. Finding alternatives for these infections is critical, for which some neglected drugs may be an option. OBJECTIVE To determine whether fosfomycin is noninferior to ceftriaxone or meropenem in the targeted treatment of bacteremic urinary tract infections (bUTIs) due to MDR E coli. DESIGN, SETTING, AND PARTICIPANTS This multicenter, randomized, pragmatic, open clinical trial was conducted at 22 Spanish hospitals from June 2014 to December 2018. Eligible participants were adult patients with bacteremic urinary tract infections due to MDR E coli; 161 of 1578 screened patients were randomized and followed up for 60 days. Data were analyzed in May 2021. INTERVENTIONS Patients were randomized 1 to 1 to receive intravenous fosfomycin disodium at 4 g every 6 hours (70 participants) or a comparator (ceftriaxone or meropenem if resistant; 73 participants) with the option to switch to oral fosfomycin trometamol for the fosfomycin group or an active oral drug or pa renteral ertapenem for the comparator group after 4 days. MAIN OUTCOMES AND MEASURES The primary outcome was clinical and microbiological cure (CMC) 5 to 7 days after finalization of treatment; a noninferiority margin of 7% was considered. RESULTS Among 143 patients in the modified intention-to-treat population (median [IQR] age, 72 [62-81] years; 73 [51.0%] women), 48 of 70 patients (68.6%) treated with fosfomycin and 57 of 73 patients (78.1%) treated with comparators reached CMC (risk difference, -9.4 percentage points; 1-sided 95% CI, -21.5 to infinity percentage points; P = .10). While clinical or microbiological failure occurred among 10 patients (14.3%) treated with fosfomycin and 14 patients (19.7%) treated with comparators (risk difference, -5.4 percentage points; 1-sided 95% CI. -infinity to 4.9; percentage points; P = .19), an increased rate of adverse event-related discontinuations occurred with fosfomycin vs comparators (6 discontinuations [8.5%] vs 0 discontinuations; P = .006). In an exploratory analysis among a subset of 38 patients who underwent rectal colonization studies, patients treated with fosfomycin acquired a new ceftriaxone-resistant or meropenem-resistant gram-negative bacteria at a decreased rate compared with patients treated with comparators (0 of 21 patients vs 4 of 17 patients [23.5%]; 1-sided P = .01). CONCLUSIONS AND RELEVANCE This study found that fosfomycin did not demonstrate noninferiority to comparators as targeted treatment of bUTI from MDR E coli; this was due to an increased rate of adverse event-related discontinuations. This finding suggests that fosfomycin may be considered for selected patients with these infections.

Published
2022

28. Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)

Author

Castón, Juan José, primary, Cano, Angela, additional, Pérez-Camacho, Inés, additional, Aguado, Jose M, additional, Carratalá, Jordi, additional, Ramasco, Fernando, additional, Soriano, Alex, additional, Pintado, Vicente, additional, Castelo-Corral, Laura, additional, Sousa, Adrian, additional, Fariñas, María Carmen, additional, Muñoz, Patricia, additional, Abril López De Medrano, Vicente, additional, Sanz-Peláez, Óscar, additional, Los-Arcos, Ibai, additional, Gracia-Ahufinger, Irene, additional, Pérez-Nadales, Elena, additional, Vidal, Elisa, additional, Doblas, Antonio, additional, Natera, Clara, additional, Martínez-Martínez, Luis, additional, and Torre-Cisneros, Julian, additional

Published
2022
Full Text
View/download PDF

30. A systematic literature review and expert consensus on risk factors associated to infection progression in adult patients with respiratory tract or rectal colonisation by carbapenemresistant Gram-negative bacteria.

Author

Ferrer, Ricard, Soriano, Alex, Cantón, Rafael, Luis Del Pozo, José, García-Vidal, Carolina, Garnacho-Montero, José, Larrosa, Nieves, Rascado, Pedro, Salavert, Miguel, Pintado, Vicente, Giró-Perafita, Ariadna, and Badia, Xavier

Subjects
MULTIDRUG resistance, CARBAPENEM-resistant bacteria, PNEUMONIA, PATIENTS' attitudes, COLONIZATION
Abstract

Copyright of Revista Española de Quimioterapia is the property of Sociedad Espanola de Quimioterapia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2022
Full Text
View/download PDF

31. Carbapenemase-producing Enterobacterales infections in COVID-19 patients

Author

Pintado, Vicente, primary, Ruiz-Garbajosa, Patricia, additional, Escudero-Sanchez, Rosa, additional, Gioia, Francesca, additional, Herrera, Sabina, additional, Vizcarra, Pilar, additional, Fortún, Jesús, additional, Cobo, Javier, additional, Martín-Dávila, Pilar, additional, Morosini, María Isabel, additional, Cantón, Rafael, additional, and Moreno, Santiago, additional

Published
2021
Full Text
View/download PDF

32. A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

Author

Gómez-Zorrilla, Silvia, Becerra-Aparicio, Federico, López Montesinos, Inmaculada, Ruiz de Gopegui, Enrique, Grau, Inmaculada, Pintado, Vicente, Padilla, Belén, Benito, Natividad, Boix-Palop, Lucía, Fariñas, Maria Carmen, Peñaranda, María, Gamallo, Maria Rocío, Martinez, Jose Antonio, Morte-Romea, Elena, Del Pozo, Jose Luis, Durán-Jordá, Xavier, Díaz-Regañón, Jazmin, López-Mendoza, Diego, Cantón, Rafael, Oliver, Antonio, Ruiz-Garbajosa, Patricia, Horcajada, Juan Pablo, Siverio, Ana, Gijón, Desiré, Merino, Irene, López-Causapé, Carla, Sabé, Nuria, Shaw, Evelyn, Berbel, Dámaris, Tubau Quintano, Fe, Sánchez Carrillo, Carlos, Cercenado, Emilia, Sendra, Elena, Rubio, Verónica, Rivera, Alba, Calvo, Esther, Badía, Cristina, Xercavins, Mariona, de Malet, Ana, Canoura-Fernández, Luis, Salvo, Soledad, Paño-Pardo, Jose Ramón, Carmona-Torre, Francisco, and Universidad de Cantabria

Subjects
Microbiology (medical), medicine.medical_specialty, Hospital-acquired infections, business.industry, medicine.drug_class, Proportional hazards model, Urinary system, Antibiotics, Logistic regression, medicine.disease, Urinary tract infections, Multiple drug resistance, Infectious Diseases, Multidrug resistant, Bacteremia, Internal medicine, Medicine, Bloodstream infections, business, Prospective cohort study, Community-onset healthcare-associated infections, Cohort study, Original Research
Abstract

Introduction: Healthcare-associated (HCA) infections represent a growing public health problem. The aim of this study was to compare community-onset healthcare associated (CO-HCA) bacteremic urinary tract infections (BUTI) and hospital-acquired (HA)-BUTI with special focus on multidrug resistances (MDR) and outcomes. Methods: ITUBRAS-project is a prospective multicenter cohort study of patients with HCA-BUTI. All consecutive hospitalized adult patients with CO-HCA-BUTI or HA-BUTI episode were included in the study. Exclusion criteria were: patients \ 18 years old, non-hospitalized patients, bacteremia from another source or primary bacteremia, non-healthcare related infections and infections caused by unusual pathogens of the urinary tract. Th main outcome variable was 30-day all-cause mortality with day 1 as the first day of positive blood culture. Logistic regression was used to analyze factors associated with clinical cure at hospital discharge and with receiving inappropriate initial antibiotic treatment. Cox regression was used to evaluate 30-day all-cause mortality. Results: Four hundred forty-three episodes were included, 223 CO-HCA-BUTI. Patients with CO-HCA-BUTI were older (p \ 0.001) and had more underlying diseases (p = 0.029) than those with HA-BUTI. The severity of the acute illness (Pitt score) was also higher in CO-HCABUTI (p = 0.026). Overall, a very high rate of MDR profiles (271/443, 61.2%) was observed, with no statistical differences between groups. In multivariable analysis, inadequate empirical treatment was associated with MDR profile (aOR 3.35; 95% CI 1.77?6.35), Pseudomonas aeruginosa (aOR 2.86; 95% CI 1.27?6.44) and Charlson index (aOR 1.11; 95% CI 1.01?1.23). Mortality was not associated with the site of acquisition of the infection or the presence of MDR profile. However, in the logistic regression analyses patients with CO-HCA-BUTI (aOR 0.61; 95% CI 0.40?0.93) were less likely to present clinical cure. Conclusion: The rate of MDR infections was worryingly high in our study. No differences in MDR rates were found between CO-HCA-BUTI and HA-BUTI, in the probability of receiving inappropriate empirical treatment or in 30-day mortality. However, CO-HCA-BUTIs were associated with worse clinical cure. Funding. This study and the journal’s Rapid Service Fee are sponsored and funded by MSD Spain. The study was also supported by Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0004, RD16/ 0016/0005, RD16/0016/0007, RD16/0016/0010, RD16/0016/0011 and RD16/0016/0015), co-financed by the European Development Regional Fund ‘A way to achieve Europe’ (ERDF), Operative program Intelligent Growth 2014–2020.

Published
2021

33. Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial

Author

Ministerio de Ciencia, Innovación y Universidades (España), Red Española de Investigación en Patología Infecciosa, Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), European Commission, Spanish Clinical Research Network, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Pujol, Miquel, Miró, José María, Shaw, Evelyn, Aguado, José María, San Juan, Rafael, Puig-Asensio, M., Pigrau, Carlos, Calbo, Esther, Montejo, Miguel, Rodríguez-Álvarez, Regino José, García-País, María José, Pintado, Vicente, Escudero-Sánchez, Rosa, López-Contreras, Joaquín, Morata, Laura, Montero, Milagros, Andrés, Marta, Pasquau-Liaño, Juan, Arenas-Miras, Maria del Mar, Padilla, Belén, Murillas, Javier, Jover-Sáenz, Alfredo, López-Cortés, Luis Eduardo, García-Prado, Graciano, Gasch, Oriol, Videla, Sebastián, Hereu, Pilar, Tebé, Cristian, Pallarès, Natalia, Sanllorente, Mireia, Domínguez, María Ángeles, Càmara, Jordi, Ferrer, Anna, Padullés, Ariadna, Cuervo, Guillermo, Carratalà, Jordi, Ministerio de Ciencia, Innovación y Universidades (España), Red Española de Investigación en Patología Infecciosa, Instituto de Salud Carlos III, Ministerio de Economía, Industria y Competitividad (España), European Commission, Spanish Clinical Research Network, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Pujol, Miquel, Miró, José María, Shaw, Evelyn, Aguado, José María, San Juan, Rafael, Puig-Asensio, M., Pigrau, Carlos, Calbo, Esther, Montejo, Miguel, Rodríguez-Álvarez, Regino José, García-País, María José, Pintado, Vicente, Escudero-Sánchez, Rosa, López-Contreras, Joaquín, Morata, Laura, Montero, Milagros, Andrés, Marta, Pasquau-Liaño, Juan, Arenas-Miras, Maria del Mar, Padilla, Belén, Murillas, Javier, Jover-Sáenz, Alfredo, López-Cortés, Luis Eduardo, García-Prado, Graciano, Gasch, Oriol, Videla, Sebastián, Hereu, Pilar, Tebé, Cristian, Pallarès, Natalia, Sanllorente, Mireia, Domínguez, María Ángeles, Càmara, Jordi, Ferrer, Anna, Padullés, Ariadna, Cuervo, Guillermo, and Carratalà, Jordi

Abstract

[Background] We aimed to determine whether daptomycin plus fosfomycin provides higher treatment success than daptomycin alone for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis., [Methods] A randomized (1:1) phase 3 superiority, open-label, and parallel group clinical trial of adult inpatients with MRSA bacteremia was conducted at 18 Spanish hospitals. Patients were randomly assigned to receive either 10 mg/kg of daptomycin intravenously daily plus 2 g of fosfomycin intravenously every 6 hours, or 10 mg/kg of daptomycin intravenously daily. Primary endpoint was treatment success 6 weeks after the end of therapy., [Results] Of 167 patients randomized, 155 completed the trial and were assessed for the primary endpoint. Treatment success at 6 weeks after the end of therapy was achieved in 40 of 74 patients who received daptomycin plus fosfomycin and in 34 of 81 patients who were given daptomycin alone (54.1% vs 42.0%; relative risk, 1.29 [95% confidence interval, .93–1.8]; P = .135). At 6 weeks, daptomycin plus fosfomycin was associated with lower microbiologic failure (0 vs 9 patients; P = .003) and lower complicated bacteremia (16.2% vs 32.1%; P = .022). Adverse events leading to treatment discontinuation occurred in 13 of 74 patients (17.6%) receiving daptomycin plus fosfomycin, and in 4 of 81 patients (4.9%) receiving daptomycin alone (P = .018)., [Conclusions] Daptomycin plus fosfomycin provided 12% higher rate of treatment success than daptomycin alone, but this difference did not reach statistical significance. This antibiotic combination prevented microbiological failure and complicated bacteremia, but it was more often associated with adverse events., [Clinical Trials Registration] NCT01898338.

Published
2021

34. A systematic review and expert’s analysis of risk factors of infections in adults due to carbapenem-resistant Pseudomonas aeruginosa or Acinetobacter baumannii in Spain

Author

Ferrer, Ricard, primary, Soriano, Alex, additional, Cantón, Rafael, additional, Del Pozo, José Luis, additional, García-Vidal, Carol, additional, Garnacho-Montero, José, additional, Larrosa, Nieves, additional, Rascado, Pedro, additional, Salavert, Miguel, additional, Pintado, Vicente, additional, Pellicer, Beatriz, additional, and Badía, Xavier, additional

Published
2021
Full Text
View/download PDF

35. Usefulness of Fecal Calprotectin in the Management of Patients with Toxigenic Clostridioides difficile

Author

Suarez-Carantoña, Cecilia, primary, Rodriguez-Torres, Argeme, additional, Viteri-Noel, Adrian, additional, Pintado, Vicente, additional, Garcia-Fernandez, Sergio, additional, Mora-Pimentel, Daniel, additional, Escudero-Sanchez, Rosa, additional, Martin-Jusdado, Fuencisla, additional, Moreno, Santiago, additional, and Cobo, Javier, additional

Published
2021
Full Text
View/download PDF

36. COVID-19 and geographical area of origin

Author

Norman, Francesca F., primary, Crespillo-Andújar, Clara, additional, Pérez-Molina, José Antonio, additional, Comeche, Belén, additional, Chamorro, Sandra, additional, Monge-Maillo, Begoña, additional, Moreno-Guillén, Santiago, additional, López-Vélez, Rogelio, additional, Vizcarra, Pilar, additional, Norman, Francesca, additional, Crespillo, Clara, additional, Pérez-Molina, José, additional, Monge, Begoña, additional, Moreno, Santiago, additional, Pérez-Elías, Maria Jesús, additional, Fortún, Jesús, additional, Navas, Enrique, additional, Quereda, Carmen, additional, Dronda, Fernando, additional, Del Campo, Santos, additional, Reinoso, Javier Cobo, additional, Casado, José Luis, additional, Moreno, Ana, additional, Martín-Dávila, Pilar, additional, Hermida, José Manuel, additional, Pintado, Vicente, additional, Serrano-Villar, Sergio, additional, Sánchez-Conde, Matilde, additional, Escudero, Rosa, additional, Gioia, Francesca, additional, Herrera, Sabina, additional, Ron, Raquel, additional, Martínez-Sanz, Javier, additional, Pons-Guillén, Mario, additional, and Vivancos, María Jesús, additional

Published
2021
Full Text
View/download PDF

37. Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients

Author

Balandin, Bárbara, primary, Ballesteros, Daniel, additional, Ruiz de Luna, Rafael, additional, López-Vergara, Loreto, additional, Pintado, Vicente, additional, Sancho-González, Milagros, additional, Soriano-Cuesta, Cruz, additional, Pérez-Pedrero, Maria José, additional, Asensio-Martín, Maria José, additional, Fernández-Simón, Inamculada, additional, Rodríguez-Serrano, Diego, additional, Silva, Alberto, additional, Chicot, Marta, additional, Iranzo, Reyes, additional, Martínez-Sagasti, Fernando, additional, and Royuela, Ana, additional

Published
2021
Full Text
View/download PDF

38. Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology

Author

Rodríguez-Baño, Jesús, Cisneros, José Miguel, Cobos-Trigueros, Nazaret, Fresco, Gema, Navarro-San Francisco, Carolina, Gudiol, Carlota, Horcajada, Juan Pablo, López-Cerero, Lorena, Martínez, José Antonio, Molina, José, Montero, Milagro, Paño-Pardo, José R., Pascual, Alvaro, Peña, Carmen, Pintado, Vicente, Retamar, Pilar, Tomás, María, Borges-Sa, Marcio, Garnacho-Montero, José, and Bou, Germán

Published
2015
Full Text
View/download PDF

40. Daptomycin plus Fosfomycin versus Daptomycin Alone for Methicillin-Resistant Staphylococcus 2 aureus Bacteremia and Endocarditis. A Randomized Clinical Trial

Author

Pujol, Miquel, Miró Meda, José M., Shaw, Evelyn, Aguado, José María, San Juan, Rafael, Puig Asensio, Mireia, Pigrau, Carles, Calbo, Esther, Montejo, Miguel, Rodriguez Álvarez, Regino, Garcia Pais, María Jose, Pintado, Vicente, Escudero Sánchez, Rosa, Lopez Contreras, Joaquín, Morata, Laura, Montero, Milagros, Andrés, Marta, Pasquau, Juan, Arenas, María del Mar, Padilla, Belén, Murillas, Javier, Jover Sáenz, Alfredo, López Cortes, Luis Eduardo, García Pardo, Graciano, Gasch, Oriol, Videla, Sebastian, Hereu, Pilar, Tebé, Cristian, Pallarès, Natàlia, Sanllorente, Mireia, Domínguez Luzón, Ma. Ángeles (María Ángeles), Càmara, Jordi, Ferrer, Anna, Padullés Zamora, Ariadna, Cuervo Requena, Guillermo, Carratalà, Jordi, and MRSA Bacteremia (BACSARM) Trial Investigators

Subjects
Clinical trials, Endocarditis, Bacteria, Antibiotics, lipids (amino acids, peptides, and proteins), Antibiòtics, biochemical phenomena, metabolism, and nutrition, Malalties infeccioses, Communicable diseases, bacterial infections and mycoses, Bacteris, Assaigs clínics
Abstract

Background We aimed to determine whether daptomycin plus fosfomycin provides higher treatment success than daptomycin alone for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia and endocarditis. Methods A randomized (1:1) phase 3 superiority, open-label, and parallel group clinical trial of adult inpatients with MRSA bacteremia was conducted at 18 Spanish hospitals. Patients were randomly assigned to receive either 10 mg/kg of daptomycin intravenously daily plus 2 g of fosfomycin intravenously every 6 hours, or 10 mg/kg of daptomycin intravenously daily. Primary endpoint was treatment success 6 weeks after the end of therapy. Results Of 167 patients randomized, 155 completed the trial and were assessed for the primary endpoint. Treatment success at 6 weeks after the end of therapy was achieved in 40 of 74 patients who received daptomycin plus fosfomycin and in 34 of 81 patients who were given daptomycin alone (54.1% vs 42.0%; relative risk, 1.29 [95% confidence interval, .93-1.8]; P = .135). At 6 weeks, daptomycin plus fosfomycin was associated with lower microbiologic failure (0 vs 9 patients; P = .003) and lower complicated bacteremia (16.2% vs 32.1%; P = .022). Adverse events leading to treatment discontinuation occurred in 13 of 74 patients (17.6%) receiving daptomycin plus fosfomycin, and in 4 of 81 patients (4.9%) receiving daptomycin alone (P = .018). Conclusions Daptomycin plus fosfomycin provided 12% higher rate of treatment success than daptomycin alone, but this difference did not reach statistical significance. This antibiotic combination prevented microbiological failure and complicated bacteremia, but it was more often associated with adverse events.

Published
2020

41. Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors

Author

Miralles, Pilar, Berenguer, Juan, Ribera, Jose Maria, Pintado, Vicente, and Rodriguez-Arrondo, Francisco

Subjects
Non-Hodgkin's lymphomas -- Prognosis, Non-Hodgkin's lymphomas -- Drug therapy, AIDS (Disease) -- Prognosis, AIDS (Disease) -- Drug therapy, Highly active antiretroviral therapy -- Health aspects, Health
Abstract

A study was conducted to assess complete remission (CR) and survival in patients with systemic AIDS-related non-Hodgkin lymphoma (ARL) receiving highly active antiretroviral therapy (HAART). It is concluded that CR was associated exclusively with tumor-related factors in patients with ARL treated with HAART and the CR rate was poorer in patients with BL and TC subtypes and was inversely correlated with IPI score.

Published
2007

42. Linezolid for therapy of Staphylococcus aureus meningitis: a cohort study of 26 patients

Author

Pintado, Vicente, Pazos, Rosario, Jiménez-Mejías, M. E., Rodríguez-Guardado, Azucena, Díaz-Pollán, Beatriz, Cabellos, Carmen, García-Lechuz, Juan Manuel, Lora-Tamayo, Jaime, Domingo, Pere, Múñez, E., Domingo, Diego, González-Romo, Fernando, Lepe, José A., Rodríguez-Lucas, Carlos, Valencia, Eulalia, Pelegrín, Iván, Chaves, F., Pomar, Virginia, Ramos, Antonio, Alarcón, Teresa, Pérez-Cecilia, Elisa, Pintado, Vicente, Pazos, Rosario, Jiménez-Mejías, M. E., Rodríguez-Guardado, Azucena, Díaz-Pollán, Beatriz, Cabellos, Carmen, García-Lechuz, Juan Manuel, Lora-Tamayo, Jaime, Domingo, Pere, Múñez, E., Domingo, Diego, González-Romo, Fernando, Lepe, José A., Rodríguez-Lucas, Carlos, Valencia, Eulalia, Pelegrín, Iván, Chaves, F., Pomar, Virginia, Ramos, Antonio, Alarcón, Teresa, and Pérez-Cecilia, Elisa

Abstract

[Background]: Linezolid has good penetration to the meninges and could be an alternative for treatment of Staphylococcus aureus meningitis. We assessed the efficacy and safety of linezolid therapy for this infection., [Methods]: Retrospective multicenter cohort study of 26 adults treated with linezolid, derived from a cohort of 350 cases of S. aureus meningitis diagnosed at 11 university hospitals in Spain (1981-2015)., [Results]: There were 15 males (58%) and mean age was 47.3 years. Meningitis was postoperative in 21 (81%) patients. The infection was nosocomial in 23 (88%) cases, and caused by methicillin-resistant S. aureus in 15 cases and methicillin-susceptible S. aureus in 11. Linezolid was given as empirical therapy in 10 cases, as directed therapy in 10, and due to failure of vancomycin in 6. Monotherapy was given to 16 (62%) patients. Median duration of linezolid therapy was 17 days (IQR 12-22 days) with a daily dose of 1,200 mg in all cases. The clinical response rate to linezolid was 69% (18/26) and microbiological response was observed in 14 of 15 cases evaluated (93%). Overall 30-day mortality was 23% and was directly associated with infection in most cases. When compared with the patients of the cohort, no significant difference in mortality was observed between patients receiving linezolid or vancomycin for therapy of methicillin-resistant S. aureus meningitis (9% vs. 20%; p = .16) nor between patients receiving linezolid or cloxacillin for therapy of methicillin-susceptible S. aureus meningitis (20% vs 14%; p = .68). Adverse events appeared in 14% (3/22) of patients, but linezolid was discontinued in only one patient., [Conclusions]: Linezolid appears to be effective and safe for therapy of S. aureus meningitis. Our findings showed that linezolid may be considered an adequate alternative to other antimicrobials in meningitis caused by S. aureus.

Published
2020

43. Analysis of mortality and risk factors associated with native valve endocarditis in drug users: the importance of vegetation size

Author

Martin-Davila, Pilar, Navas, Enrique, Fortun, Jesus, Moya, Jose Luis, Cobo, Javier, Pintado, Vicente, Quereda, Carmen, Jimenez-Mena, Manuel, and Moreno, Santiago

Subjects
Endocarditis -- Patient outcomes, Endocarditis -- Risk factors, Heart valve diseases -- Research, Drug addicts -- Health aspects, Drug addicts -- Research, Mortality -- Risk factors, Health
Published
2005

47. Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort

Author

Vizcarra, Pilar, primary, Pérez-Elías, María J, additional, Quereda, Carmen, additional, Moreno, Ana, additional, Vivancos, María J, additional, Dronda, Fernando, additional, Casado, José L, additional, Moreno, Santiago, additional, Pérez-Elías, Maria Jesús, additional, Fortún, Jesús, additional, Navas, Enrique, additional, Del Campo, Santos, additional, López-Vélez, Rogelio, additional, Cobo Reinoso, Javier, additional, Casado, José Luis, additional, Norman, Franceca, additional, Martín-Dávila, Pilar, additional, Hermida, José Manuel, additional, Pérez Molina, José Antonio, additional, Monge, Begoña, additional, Pintado, Vicente, additional, Serrano-Villar, Sergio, additional, Sánchez-Conde, Matilde, additional, Chamorro, Sandra, additional, Escudero, Rosa, additional, Gioia, Francesca, additional, Comeche, Belén, additional, Crespillo, Clara, additional, Herrera, Sabina, additional, Ron, Raquel, additional, Martínez-Sanz, Javier, additional, Pons-Guillén, Mario, additional, Vivancos, María Jesús, additional, and Vizcarra, Pilar, additional

Published
2020
Full Text
View/download PDF

48. Linezolid for therapy of Staphylococcus aureus meningitis: a cohort study of 26 patients

Author

Pintado, Vicente, primary, Pazos, Rosario, additional, Jiménez-Mejías, Manuel Enrique, additional, Rodríguez-Guardado, Azucena, additional, Díaz-Pollán, Beatriz, additional, Cabellos, Carmen, additional, García-Lechuz, Juan Manuel, additional, Lora-Tamayo, Jaime, additional, Domingo, Pere, additional, Muñez, Elena, additional, Domingo, Diego, additional, González-Romo, Fernando, additional, Lepe-Jiménez, José Antonio, additional, Rodríguez-Lucas, Carlos, additional, Valencia, Eulalia, additional, Pelegrín, Iván, additional, Chaves, Fernando, additional, Pomar, Virginia, additional, Ramos, Antonio, additional, Alarcón, Teresa, additional, and Pérez-Cecilia, Elisa, additional

Published
2020
Full Text
View/download PDF

49. Carbapenemase-producing Enterobacterales infections in COVID-19 patients.

Author

Pintado, Vicente, Ruiz-Garbajosa, Patricia, Escudero-Sanchez, Rosa, Gioia, Francesca, Herrera, Sabina, Vizcarra, Pilar, Fortún, Jesús, Cobo, Javier, Martín-Dávila, Pilar, Morosini, María Isabel, Cantón, Rafael, and Moreno, Santiago

Subjects
*COVID-19, *NOSOCOMIAL infections, *KLEBSIELLA infections, *SERRATIA marcescens, *ENTEROBACTER cloacae, *KLEBSIELLA pneumoniae
Abstract

Carbapenemase-producing Enterobacterales (CPE) infections have been occasionally described in patients with coronavirus disease-19 (COVID-19). We assess the clinical features and outcome of these infections. In this retrospective single-centre, case-control study, we included 54 patients with CPE infection: 30 case-patients (COVID-19) and 24 controls (non-COVID-19), collected between March and May 2020. We compared the epidemiological, clinical features, and outcome between cases and controls. CPE infection was more frequent in COVID-19 patients than in controls (1.1 vs. 0.5%, p =.005). COVID-19 patients were younger, had a lower frequency of underlying diseases (p =.01), and a lower median Charlson score (p =.002). Predisposing factors such as antimicrobial use, mechanical ventilation, or ICU admission, were more frequent in COVID-19 patients (p <.05). There were 73 episodes of infection (42 cases and 31 controls) that were more frequently hospital-acquired and diagnosed at the ICU in COVID-19 patients (p <.001). Urinary tract was the most common source of infection (47.9%), followed by pneumonia (23.3%). The frequency of severe sepsis or shock (p =.01) as well as the median SOFA score (p =.04) was higher in cases than in controls. Klebsiella pneumoniae (80.8%), Serratia marcescens (11%) and Enterobacter cloacae (4.1%) were the most common bacteria in both groups (KPC 56.2%, OXA-48 26% and VIM 17.8%). Overall 30-d mortality rate of COVID-19 patients and controls was 30 and 16.7%, respectively (p =.25). COVID-19 patients have an increased risk of CPE infections, which usually present as severe, nosocomial infections, appearing in critically-ill patients and associated with a high mortality. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results